Document text
Principal Investigator: Michael Schotsaert
Organization: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Fiscal Year: 2024
Award: $264,250
Funding agency: National Institute of Allergy and Infectious Diseases
Abstract
Respiratory viruses spread from host to host as they are shed from mucosal surfaces and can transmit through
the air or via surface contact. Therefore, it is believed that the induction of a strong mucosal immune defense
cannot only prevent from infection at the port of virus entry, but also affect virus transmission, thereby preventing
new infections. In this proposal, we will address the impact of mucosal adjuvanted vaccination on the outcome
of disease, host immune responses to and transmission events after experimental respiratory infection with
influenza virus and SARS-CoV-2. We will use the guinea pig (influenza) and Syrian golden hamster (SARS-CoV-
2), two established models for vaccination, infection and transmission studies with respiratory viruses. Intranasal
virus inoculation will result in replication mainly in the upper respiratory tract for guinea pigs, whereas SARS-
CoV-2 will replicate in both upper and lower respiratory tract. We will compare protection provided by mucosal
adjuvanted vaccination via the intranasal route to parenteral vaccination via the intramuscular route and will
investigate the impact of induction of protective immune responses at mucosal sites on host immune responses
to infection in vaccinated hosts (hybrid immunity) and virus transmission between vaccinated infected animals
and naïve receiver animals. Despite being vaccine-preventable diseases, transmission of influenza and SARS-
CoV-2 occurs frequently after breakthrough infection of antigenically drifted virus variants in vaccinated people.
For this R21, three principal investigators with complementary expertise in preclinical animal models for
respiratory virus transmission, mucosal adjuvanted vaccines and immune profiling will continue to build on their
previous collaborative efforts and expertise to investigate the potential of an intranasal mucosal adjuvanted
vaccine strategy previously validated in mice. The mucosal adjuvant consists of a nanoemulsion with TLR-
agonistic properties combined with a RIG-I agonist. This combination adjuvant is currently being tested and
compared to other licensed intramuscular adjuvants by us in mice for its suitability as a mucosal adjuvanted
vaccination strategy for universal and supraseasonal influenza and SARS-CoV-2 vaccine antigens. The
efficiency of inhibition of transmission by mucosal vaccination will be compared to parenteral vaccination with
the current standards of care for populations at risk (split inactivated influenza virus vaccine or recombinant
hemagglutinin for influenza and mRNA or adjuvanted recombinant SARS-CoV-2 spike protein-based COVID-19
vaccines). We will correlate induced mucosal and systemic immune responses after vaccination with protection
from experimental infection, reduction in transmission to naive receiver animals and enhancement of hybrid
immunity (immunity as a result of vaccination and infection).
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><Address><Adjuvant><Adverse effects><Affect><Agonist><Air><Airway infections><Animal Model><Animal Models and Related Studies><Animals><Antibodies><B.1.351><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 S protein><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 period><COVID-19 public health crisis><COVID-19 spike><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 transmission><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID-19 virus transmission><COVID-19 years><COVID19 virus><Caring><Cavia><CoV-2><CoV2><Conchae Nasales><Convalescence><Coronaviridae><Coronavirus><Cricetinae><Disease><Disease Outcome><Disorder><Environmental Factor><Environmental Risk Factor><Epidemic><Event><Golden Hamsters><Golden Syrian Hamsters><Grippe><Groups at risk><Guinea Pigs><Guinea Pigs Mammals><Hamsters><Hamsters Mammals><Host Factor><Host Factor Protein><Hybrids><Immune><Immune response><Immunes><Immunity><Immunological response><Infection><Infection prevention><Influenza><Influenza HA><Influenza Hemagglutinin><Influenza Vaccines><Influenza Virus><Integration Host Factors><Intramuscular><Licensing><Lower respiratory tract structure><Lung><Lung Respiratory System><Mediating><Mesocricetus auratus><Messenger RNA><Mice><Mice Mammals><Modeling><Monitor><Mucosa><Mucosal Tissue><Mucous Membrane><Murine><Mus><Nasal><Nasal Passages Nose><Nasal turbinate bone structure><Nose><Outcome><Pathology><People at risk><Persons at risk><Populations at Risk><Pre-Clinical Model><Preclinical Models><Prevent infection><Principal Investigator><Property><Pulmonary Body System><Pulmonary Organ System><Recombinants><Regimen><Respiratory Infections><Respiratory System><Respiratory System, Nose, Nasal Passages><Respiratory Tract Infections><Respiratory Tracts><Respiratory tract structure><Route><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 B.1.351><SARS-CoV-2 S><SARS-CoV-2 S protein><SARS-CoV-2 beta><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV-2 spike><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 transmission><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Solid><South Africa strain><South Africa variant><South African strain><South African variant><Surface><Syrian Hamsters><Testing><Transmission><Turbinates><Upper respiratory tract><Vaccinated><Vaccination><Vaccine Antigen><Vaccinee><Vaccines><Variant><Variation><Viral Diseases><Viral Shedding><Virus><Virus Diseases><Virus Replication><Virus Shedding><Wuhan coronavirus><breakthrough infection><corona virus><coronavirus disease 2019 S protein><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 transmission><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease 2019 virus transmission><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><environmental risk><experience><flu HA><flu hemagglutinin><flu infection><flu transmission><flu vaccine><flu virus infection><flu virus vaccine><guinea pig model><hCoV19><host response><immune system response><immunization strategy><immunoresponse><infected with flu><infected with flu virus><infected with influenza><infected with influenza virus><influenza infection><influenza transmission><influenza viral HA><influenza viral hemagglutinin><influenza virus HA><influenza virus hemagglutinin><influenza virus infection><influenza virus vaccine><influenzavirus><lower respiratory tract><mRNA><model of animal><mucosal site><mucosal vaccination><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><nano emulsion><nanoemulsion><outcome following vaccination><outcome following vaccine><pandemic><pandemic disease><pre-clinical><preclinical><prevent><preventing><pulmonary><respiratory infection virus><respiratory virus><response><result following vaccination><result following vaccine><severe acute respiratory syndrome coronavirus 2 B.1.351><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 transmission><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><spike proteins on SARS-CoV-2><standard of care><transmission of the flu virus><transmission process><transmitted COVID-19><transmitted SARS-CoV-2><transmitted coronavirus disease 2019><transmitted severe acute respiratory syndrome coronavirus 2><upper airway tract><vaccinated individual><vaccinated participant><vaccinated patient><vaccinated person><vaccinated subject><vaccination outcome><vaccination result><vaccination strategy><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine against flu><vaccine against influenza><vaccine candidates against SARS-CoV-2><vaccine for novel coronavirus><vaccine outcome><vaccine response><vaccine responsiveness><vaccine result><vaccine safety><vaccine strategy><vaccine-induced response><vaccines preventing COVID><vaccines to prevent COVID><variants of concern><viral infection><viral multiplication><viral replication><viral transmission><virus infection><virus multiplication><virus transmission><virus-induced disease>